Adrenocortical Carcinoma - Pipeline Insight, 2024

This “Adrenocortical Carcinoma- Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Adrenocortical Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Adrenocortical Carcinoma: Understanding

Adrenocortical Carcinoma: Overview

Adrenocortical carcinoma is cancer that forms in the outer layer (cortex) of the adrenal glands. There are two adrenal glands, one located at the top of each kidney. The adrenal cortex makes hormones - including cortisol, testosterone, aldosterone and estrogen. These hormones control male and female traits and body functions such as blood pressure and response to stress. An adrenocortical carcinoma (ACC) is a cancerous adrenal tumor that forms in the adrenal cortex. There are two types of ACC:
Functioning ACC tumor: A functioning ACC tumor causes your adrenal gland to make more hormones than it normally should.- Nonfunctioning ACC tumor: This type of tumor doesn’t affect hormone production.

Adrenal tumors cause symptoms in two ways:

• A functioning ACC can cause symptoms related to the overproduction of hormones.
• If the adrenal tumor grows large enough, it may press on nearby organs. This pressure can cause pain or other symptoms.

Depending on the cause, symptoms of adrenocortical carcinoma may include abdominal (belly) pain, breast enlargement in boys or men (gynecomastia), early puberty in boys or girls, growth of excess facial or body hair in women, high blood pressure, and high blood sugar.

Weight gain in the face, neck and trunk (but not arms and legs).

The healthcare provider will start with a physical exam to diagnose afrenocortical carcinoma. If symptoms point to adrenal cancer, the following diagnostic tests must be conducted:

• Imaging tests, such as MRI, CT scan or PET scan to look for tumors.
• Blood and urine tests to check hormone levels.
• A dexamethasone suppression test to measure cortisol levels.
• Biopsy to determine if a tumor is cancerous.

The first treatment is usually surgery to remove the tumor. The surgeon would remove adrenal gland and may need to remove other nearby tissue, too. To stop cancerous cells from spreading to other areas of your body, the treatment plan may include radiation, chemotherapy and immunotherapy.

Adrenocortical Carcinoma- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Adrenocortical Carcinoma pipeline landscape is provided which includes the disease overview and Adrenocortical Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Adrenocortical Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Adrenocortical Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Adrenocortical Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Adrenocortical Carcinoma.

Adrenocortical Carcinoma Emerging Drugs Chapters

This segment of the Adrenocortical Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Adrenocortical Carcinoma Emerging Drugs

Relacorilant: Corcept TherapeuticsRelacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor, the receptor for cortisol which is activated when cortisol levels are high. Relacorilant does not bind to the body's other hormone receptors. Corcept is studying relacorilant as a potential treatment for a variety of serious disorders, including Cushing's syndrome and advanced adrenal, ovarian and pancreatic cancer.

Ipilimumab: Bristol-Myers SquibbYervoy is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). CTLA-4 is a negative regulator of T-cell activity. Yervoy binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor infiltrating T-effector cells. Inhibition of CTLA-4 signaling can also reduce T-regulatory cell function, which may contribute to a general increase in T-cell responsiveness, including the anti-tumor immune response. The drug is in phase 2 of clinical trials for the treatment of adrenocortical carcinoma.

Adrenocortical Carcinoma: Therapeutic Assessment

This segment of the report provides insights about the different Adrenocortical Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Adrenocortical Carcinoma

There are approx. 5+ key companies which are developing the therapies for Adrenocortical Carcinoma. The companies which have their Adrenocortical Carcinoma drug candidates in the most advanced stage, i.e. pre-registration include, CRISPR Therapeutics.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Adrenocortical Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Adrenocortical Carcinoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Adrenocortical Carcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adrenocortical Carcinoma drugs.

Adrenocortical Carcinoma Report Insights

• Adrenocortical Carcinoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Adrenocortical Carcinoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Adrenocortical Carcinoma drugs?
• How many Adrenocortical Carcinoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Adrenocortical Carcinoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Adrenocortical Carcinoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Adrenocortical Carcinoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Corcept Therapeutics
• Bristol-Myers Squibb
• Enterome
• Exelixis/Ipsen
• Genentech

Key Products

• Relacorilant
• Ipilimumab
• EO 2401
• Cabozantinib
• Atezolizumab

This product will be delivered within 1-3 business days.